Method for simultaneously determining 10 tryptophan metabolites through liquid chromatography-mass spectrometry

By optimizing sample pretreatment and detection parameters using liquid chromatography-tandem mass spectrometry, the problem of simultaneously determining tryptophan metabolites was solved, enabling systematic and multidimensional quantitative analysis of UC model rats and biological samples after intervention, and revealing the metabolic regulatory mechanism of Shenling Baizhu Powder.

CN121878075APending Publication Date: 2026-04-17JIANGXI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202610125726.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-01-29
Publication Date
2026-04-17

AI Technical Summary

Technical Problem

Existing technologies are difficult to use to systematically, sensitively, and specifically determine multiple metabolites in the tryptophan metabolic network simultaneously, which limits the systematic, multi-target quantitative analysis and biomarker application of the tryptophan metabolic pathway in ulcerative colitis (UC).

Method used

By employing liquid chromatography-tandem mass spectrometry (LC-MS/MS), optimizing sample pretreatment procedures, chromatographic separation conditions, and mass spectrometry detection parameters, and combining internal standard calibration, a LC-MS/MS method was established to simultaneously determine 10 key metabolites in UC model rats and biological samples after intervention.

Benefits of technology

It enables systematic and multidimensional quantitative analysis of fecal, serum, colon tissue and cell samples, eliminates matrix interference, ensures data reliability and reproducibility, and provides an innovative tool for the study of metabolic regulation mechanisms of UC.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN121878075A_ABST
    Figure CN121878075A_ABST
Patent Text Reader

Abstract

The invention belongs to the field of analytical chemistry, and provides a method for simultaneously determining 10 tryptophan metabolites through liquid chromatography-mass spectrometry, differentiated pretreatment schemes are designed aiming at different biological matrixes such as excrement, serum, colon tissue and NCM460 inflammatory cells through a liquid chromatography-tandem mass spectrometry technology, matrix interference is effectively eliminated, and the method for simultaneously determining 10 tryptophan metabolites through liquid chromatography-mass spectrometry is provided. A quantitative analysis method with high sensitivity and high selectivity is established; the method is successfully applied to an ulcerative colitis (UC) rat model and a lipopolysaccharide (LPS)-induced NCM460 inflammation model, and a technical means is provided for revealing a metabolic regulation mechanism of medicine intervention on UC; the method solves the technical problem that various metabolites in a tryptophan metabolic pathway are difficult to detect in the prior art, is suitable for metabolic mechanism research, drug intervention effect evaluation and large-scale detection of clinical samples of inflammatory bowel diseases such as UC, and provides a technical basis for systematic research of a tryptophan metabolic network.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of analytical chemistry and relates to the detection of tryptophan and its metabolites, specifically to a method for simultaneously determining 10 tryptophan metabolites using liquid chromatography-mass spectrometry. Background Technology

[0002] Ulcerative colitis (UC) is a chronic, relapsing, nonspecific inflammatory disease of the colon, primarily affecting the rectal and colonic mucosa and submucosa. Its protracted course severely impacts patients' quality of life; therefore, effective treatment and prognostic assessment are of significant clinical importance. Studies have shown that the development of UC is closely related to metabolic disorders, with abnormalities in the tryptophan (TRP) metabolic pathway receiving widespread attention. Tryptophan, an essential amino acid, is mainly metabolized through the kynurenine pathway, serotonin pathway, and indole pathway. Its metabolites play crucial roles in maintaining intestinal barrier function, immune regulation, and neuroendocrine homeostasis.

[0003] Studies have confirmed significant tryptophan metabolism disorders in UC patients and animal models, characterized by decreased tryptophan levels and increased concentrations of downstream metabolites such as kynurenine (KYN) and serotonin (5-HT), while concentrations of indoleacetic acid (IAA) and indole-3-propionic acid (IPA) are decreased. These metabolic changes are significantly correlated with the inflammatory activity, disease stage, and degree of mucosal damage in UC, suggesting that the tryptophan metabolic pathway may be an important target for UC intervention. Regulating this pathway through pharmacological or dietary means can effectively alleviate intestinal inflammation and improve barrier function. However, current research focuses on single or a few metabolites, and systematic, multi-target quantitative analysis of the tryptophan metabolic network in different pathological stages of UC and in different biological samples (such as feces, serum, and tissues) is still lacking. This limits the overall understanding of its metabolic profile and its in-depth application as a biomarker or therapeutic monitoring indicator.

[0004] Therefore, in order to further elucidate the role of tryptophan metabolism in the pathogenesis of UC and the metabolic regulation mechanism of traditional Chinese medicine intervention, this invention aims to establish a systematic and highly sensitive quantitative analysis method. Liquid chromatography-tandem mass spectrometry (LC-MS / MS) was used to simultaneously measure the tryptophan metabolic pathway in four biological samples: feces, serum, colonic tissue from UC model rats, and a lipopolysaccharide (LPS)-induced human normal colonic epithelial cell 460 (NCM460) inflammation model. These samples included LPS-induced NCM460 colonic epithelial inflammatory cell model. The tryptophan metabolic pathway was analyzed using four different samples: tryptophan (TRP), kynurenine (KYN), kynurenic acid (KYNA), 5-hydroxytryptamine (5-HT), 5-hydroxyindoleacetic acid (5-HIAA), 3-hydroxykynurenine (3-HK), 3-hydroxyanthranilic acids (3-AA), 3-indoleacetic acid (IAA), and indolyl-3-propionic acid. The study included the levels of 10 key metabolites, including kynurenine (KYN), xanthurenic acid (XA), and KYNA. Of the 10 substances tested, KYN, KYNA, 3-HK, 3-AA, and XA were associated with the kynurenine pathway; 5-HT and 5-HIAA were associated with the serotonin pathway; and IAA and IPA were associated with the indole pathway. Summary of the Invention

[0005] The purpose of this invention is to provide a method for the simultaneous determination of 10 tryptophan metabolites using liquid chromatography-mass spectrometry (LC-MS). By optimizing the sample pretreatment process, chromatographic separation conditions, and mass spectrometry detection parameters, and by using an internal standard for calibration, this method solves the problem that existing technologies cannot systematically, sensitively, and specifically determine multiple metabolites with significantly different physicochemical properties in the tryptophan metabolic network.

[0006] To achieve the above objectives, the technical solution of the present invention is as follows: a method for simultaneous determination of 10 tryptophan metabolites using liquid chromatography-mass spectrometry (LC-MS), wherein the 10 tryptophan metabolites are TRP, KYN, KYNA, 5-HT, 5-HIAA, 3-AA, 3-HK, IAA, IPA, and XA; the method includes the following steps:

[0007] S1. Prepare blank biological matrix and perform sample pretreatment for samples 1-4 respectively;

[0008] S2. The samples processed in S1 were subjected to methodological determination using mass spectrometry and liquid chromatography-mass spectrometry.

[0009] Preferably, in step S1, sample 1 is a fecal sample, sample 2 is a serum sample, sample 3 is a colon sample, and sample 4 is an NCM460 inflammatory cell sample.

[0010] Preferably, the method for preparing the blank biological matrix in step S1 is as follows:

[0011] Sample 1 and Sample 3: Weigh 20.0 mg of sample, add 0.4 mL of ultrapure water, homogenize for 5 min, centrifuge, and collect the supernatant. Add 20 mg of activated carbon and 20 mg of calcite to the supernatant, and stir on a magnetic stirrer for 2 h. Centrifuge again and collect the supernatant, which is the blank matrix. The centrifugation parameters are: 17500 r·min. -1 4 ℃, 10 min;

[0012] Samples 2 and 4: 10 mg each of activated carbon and calcite were added to each 100 μL sample, and the mixture was stirred on a magnetic stirrer for 2 h. After centrifugation, the supernatant was collected, and the process was repeated 4 times. The supernatant collected after the last centrifugation was used as the blank matrix. The centrifugation parameters were: 17500 r·min -1 4 ℃, 10 min.

[0013] Preferably, the sample pretreatment method in step S1 is as follows:

[0014] Samples 1 and 3: Weigh 20.0 mg of sample, add 0.4 mL of ultrapure water, homogenize for 5 min, then take 200 μL of homogenate, add 10 μL of internal standard solution, vortex for 15 s, then add 200 μL each of methanol and acetonitrile, vortex again for 1 min, centrifuge, collect the supernatant, evaporate the supernatant to dryness, add 100 μL of 50% methanol-water solution to redissolve, centrifuge again, and collect the supernatant, which is the test solution; the centrifugation parameters are: 17500 r·min -1 The homogenization temperature is 3-6 ℃ for 10 min; 4 ℃ for 10 min.

[0015] Sample 2: Take 10 μL of sample into an EP tube, add 10 μL of internal standard solution, 200 μL each of methanol and acetonitrile, vortex for 1 min, let stand for 2 h, centrifuge, collect the supernatant, evaporate the supernatant to dryness, add 100 μL of 50% methanol-water to reconstitute, centrifuge again, and collect the supernatant, which is the test solution; the centrifugation parameters are: 17500 r·min -1 4 ℃, 10 min;

[0016] Sample 4: Take 200 μL of sample supernatant into an EP tube, add 10 μL of internal standard solution, 200 μL each of methanol and acetonitrile, vortex for 1 min, and let stand in a refrigerator at 4 ℃ for 2 h. After centrifugation, take the supernatant, evaporate the supernatant to dryness, add 100 μL of 50% methanol-water to reconstitute, centrifuge again, and take the supernatant, which is the test solution; the centrifugation parameters are: 17500 r·min -1 4 ℃, 10 min.

[0017] Preferably, the mass liquid chromatography-mass spectrometry (MS / MS) used in step S2 includes chromatography and mass spectrometry.

[0018] The chromatographic parameters were as follows: mobile phase: 0.05% formic acid-acetonitrile; flow rate: 0.1 mL / min. -1 Column temperature: 40℃; Injection volume: 1 μL; ACE C18 column: 100 mm × 2.1 mm, 3 μm; Gradient elution of all substances in positive ion mode;

[0019] The parameters of the mass spectrometer are as follows: curtain gas: 35 psi, 160.88 kPa; nebulizer gas: 45 psi, 301.28 kPa; auxiliary heater: 45 psi, 301.28 kPa; ionization temperature: 500 ℃; spray voltage: 5500 V.

[0020] Preferably, the methodological determination in step S2 includes the following steps:

[0021] A. Specificity determination: Detection of chromatograms of blank matrix, blank matrix with reference standard and internal standard, and test sample with internal standard solution to assess the interference between endogenous substances and target components and internal standards;

[0022] B. Establishment of standard curves: Prepare a series of standard curve samples with different concentrations. Use the ratio of the peak area of ​​the analyte to the peak area of ​​the internal standard as the Y-axis and the concentration as the X-axis to perform linear regression and establish the standard curve equations for 10 components.

[0023] C. Matrix effect assessment: The peak area measured by direct injection of the control solution is A, and the peak area measured by injection of the blank matrix with internal standard is B. The B / A ratio is calculated to assess the matrix effect at different concentrations.

[0024] D. Determination of absolute recovery: The peak area measured by injecting the quality control sample after extraction is C, and the peak area measured by directly injecting the control solution is A. The C / A ratio is calculated to evaluate the extraction recovery rate.

[0025] E. Precision / Accuracy Measurement:

[0026] Intraday precision / accuracy: Five quality control samples with different concentrations were measured on the same day, and the RSD and the ratio of actual concentration to theoretical concentration were calculated.

[0027] Intraday precision / accuracy: Three batches of quality control samples with different concentrations were measured on different days, and the RSD and the ratio of actual concentration to theoretical concentration were calculated.

[0028] F. Stability assessment:

[0029] In-system stability of the autosampler: RSD changes were investigated at 4 °C for 0–24 h.

[0030] Repeated freeze-thaw stability: The RSD was measured after three freeze-thaw cycles at -20 °C.

[0031] Long-term freezing stability: RSD was measured at different time points after storage at -20 ℃ for 0-30 days.

[0032] The present invention further provides the application of the above method in detecting the content of tryptophan and its metabolites.

[0033] Preferably, when the test sample is feces, serum, or colon tissue, the steps are as follows:

[0034] (1) Model construction: A UC model was established using sodium dextran sulfate combined with dietary and environmental interventions;

[0035] (2) Drug intervention: The model rats were randomly divided into the UC model group, the positive control group and the Shenling Baizhu powder group, and were administered the drug for 30 consecutive days;

[0036] (3) Sample collection;

[0037] (4) Detection.

[0038] Preferably, the positive control group in step (2) is the positive control drug sulfasalazine, and the dosage of sulfasalazine is 0.2 g·kg. -1 ·d -1 The dosage of the aforementioned Shenling Baizhu Powder is 0.945-3.78 g·kg. -1 ·d -1 .

[0039] Preferably, when the test sample is NCM460 inflammatory cells, the steps are as follows: use 40 μg·mL -1 An inflammation model was established by stimulating NCM460 cells with LPS, and the cells were treated with serum containing 5%-20% Shenling Baizhu powder and 50 μg / mL of the drug. -1 Intervention with tryptophan.

[0040] The beneficial effects of this invention are:

[0041] 1. Systematic and multidimensional quantitative analysis capability: A unified analysis method has been established that can be applied simultaneously to four biological samples: feces, serum, colon tissue and cells, enabling comprehensive and comparable studies of the tryptophan metabolic pathway at different levels of systems, tissues and cells.

[0042] 2. Excellent resistance to matrix interference: Differentiated processing methods were designed for different samples, and internal standards were used for correction, effectively eliminating matrix effects. Method validation showed that intra-day and inter-day precision and accuracy met the requirements for biological sample analysis, ensuring data reliability and reproducibility.

[0043] 3. Providing innovative tools for mechanism research: This method was successfully applied to rat models of UC and LPS-induced cell inflammation models. From the perspective of tryptophan metabolism network, it revealed the potential metabolic regulatory mechanism of Shenling Baizhu Powder in intervention of UC, providing key quantitative analysis methods and metabolomics evidence for modern research. Attached Figure Description

[0044] Figure 1 This is a specificity graph of 3-AA, 3-HK, IAA, IPA and XA in rat fecal samples in this invention (A is blank matrix, B is blank matrix with test substance, reference standard and internal standard; C is fecal sample of UC model group with internal standard, the horizontal axis is t / min, the vertical axis is Intensity, CPS).

[0045] Figure 2 This is a specificity graph of TRP, KYN, KYNA, 5-HT and 5-HIAA in rat fecal samples in this invention (A is blank matrix, B is blank matrix with test substance, reference standard and internal standard; C is fecal sample of UC model group with internal standard, the horizontal axis is t / min, the vertical axis is Intensity, CPS).

[0046] Figure 3 This is a specificity graph of 3-AA, 3-HK, IAA, IPA and XA in rat serum samples in this invention (A is blank matrix, B is blank matrix with test substance, reference standard and internal standard; C is fecal sample of UC model group with internal standard, the horizontal axis is t / min, the vertical axis is Intensity, CPS).

[0047] Figure 4 This is a specificity graph of TRP, KYN, KYNA, 5-HT and 5-HIAA in rat serum samples in this invention (A is blank matrix, B is blank matrix with test substance, control and internal standard; C is fecal sample of UC model group with internal standard, the horizontal axis is t / min, the vertical axis is Intensity, CPS).

[0048] Figure 5This is a specificity graph of 3-AA, 3-HK, IAA, IPA and XA in rat colon samples in this invention (A is blank matrix, B is blank matrix with test substance, reference standard and internal standard; C is fecal sample of UC model group with internal standard, the horizontal axis is t / min, the vertical axis is Intensity, CPS).

[0049] Figure 6 This is a specificity graph of TRP, KYN, KYNA, 5-HT and 5-HIAA in rat colon samples in this invention (A is blank matrix, B is blank matrix with test substance, reference standard and internal standard; C is fecal sample of UC model group with internal standard, the horizontal axis is t / min, the vertical axis is Intensity, CPS).

[0050] Figure 7 This is a specificity diagram of 3-AA, 3-HK, IAA, IPA and XA in NCM460 inflammatory cell samples in this invention (A is blank matrix, B is blank matrix with test substance, control and internal standard; C is fecal sample of UC model group with internal standard, the horizontal axis is t / min, the vertical axis is Intensity, CPS).

[0051] Figure 8 This is a specificity diagram of TRP, KYN, KYNA, 5-HT and 5-HIAA in NCM460 inflammatory cell samples in this invention (A is blank matrix, B is blank matrix with test substance, control and internal standard; C is fecal sample of UC model group with internal standard, the horizontal axis is t / min, the vertical axis is Intensity, CPS).

[0052] Figure 9 This is a graph showing the results of the content of tryptophan and its related metabolites in fecal samples in this invention;

[0053] Figure 10 This is a graph showing the results of tryptophan and its related metabolites content in serum samples in this invention;

[0054] Figure 11 This is a graph showing the results of tryptophan and its related metabolites content in colon samples in this invention;

[0055] Figure 12 This is a graph showing the results of tryptophan and its related metabolites content in NCM460 inflammatory cell samples in this invention. Detailed Implementation

[0056] To make the objectives, technical solutions, and advantages of this invention clearer, the invention will be further described in detail below with reference to specific embodiments. It should be understood that the specific embodiments described herein are merely illustrative and not intended to limit the invention.

[0057] Example 1

[0058] Measurement conditions based on UPLC-MS / MS

[0059] 1. Chromatographic conditions

[0060] LC-30AD Shimadzu liquid chromatography (column oven: CTO30A; degasser: DGU-20A5; autosampler: SIL-30AC) - AB 5500 series triple quadrupole mass spectrometer (data acquisition and processing software: Analyst 1.6.2); chromatographic conditions: mobile phase: 0.05% formic acid water (A) - acetonitrile (B); flow rate: 0.1 mL·min -1 Column temperature: 40 ℃; Injection volume: 1 μL; ACE C18 column (100 mm × 2.1 mm, 3 μm); Gradient elution was performed for all substances in positive ion mode, and the elution program is shown in Table 1.

[0061] Table 1 Gradient elution procedure in positive mode

[0062]

[0063] 2. Mass spectrometry conditions

[0064] Multiple reaction monitoring (MRM) and electrospray ionization (ESI) positive mode scans were performed. The main mass spectrometry parameters were: curtain gas (CUR): 35 psi (160.88 kPa); nebulizer gas (GS1): 45 psi (301.28 kPa); auxiliary heater (GS2): 45 psi (301.28 kPa); ionization temperature (TEM): 500 ℃; spray voltage (IS): 5500 V. The ion pairs of each analyte and the optimized declustering voltage (DP) and collision energy (CE) parameters are shown in Table 2.

[0065] Table 2 Mass spectrometry parameters of each analyte component's daughter ion and parent ion

[0066]

[0067] Example 2 Sample Processing

[0068] 1. Preparation of blank biological substrate

[0069] 1.1 Fecal samples

[0070] Weigh 20.0 mg of blank rat feces, add 0.4 mL of ultrapure water, homogenize for 5 min, centrifuge and collect the supernatant (17500 r·min). -1Add 20 mg of activated carbon and 20 mg of calcite to the supernatant (4 ℃, 10 min), stir on a magnetic stirrer for 2 h, and centrifuge to collect the supernatant (17500 r·min). -1 (4 ℃, 10 min). The supernatant collected is used as a blank matrix and can be used to prepare standard curves and quality control samples for fecal samples.

[0071] 1.2 Serum Samples

[0072] Add 10 mg each of activated charcoal and calcite to every 100 μL of serum, stir on a magnetic stirrer for 2 h, centrifuge and collect the supernatant (17500 r·min). -1 (4 ℃, 10 min), repeated 4 times. The supernatant collected after the last centrifugation is the blank matrix, which can be used to prepare serum sample standard curves and quality control samples.

[0073] 1.3 Colon Samples

[0074] Weigh 20.0 mg of rat colon, add 0.4 mL of ultrapure water, homogenize for 5 min, centrifuge and collect all supernatant (17500 r·min). -1 (4 ℃, 10 min), add 10.0 mg each of activated carbon and calcite to every 100 μL of supernatant, stir on a magnetic stirrer for 2 h, centrifuge and collect the supernatant (17500 r·min). -1 (4 ℃, 10 min), repeated twice. The supernatant collected is used as a blank matrix and can be used to prepare standard curves for colon samples and quality control samples.

[0075] 1.4 NCM460 inflammatory cell samples

[0076] Following the serum treatment method, add 10 mg each of activated charcoal and calcite to every 100 μL of cell supernatant, stir on a magnetic stirrer for 2 h, and centrifuge to collect the supernatant (17500 r·min). -1 Centrifugation was carried out at 4 ℃ for 10 min, and the process was repeated 4 times. The supernatant obtained from the last centrifugation was used as the blank matrix for the preparation of standard curves and quality control samples.

[0077] 2. Sample pretreatment

[0078] 2.1 Fecal samples

[0079] Weigh 20.0 mg of rat feces, add 0.4 mL of ultrapure water, homogenize for 5 min, then take 200 μL of the homogenate, add 10 μL of internal standard solution, vortex for 15 s, then add 200 μL each of methanol and acetonitrile, vortex again for 1 min, centrifuge and collect the supernatant (4 ℃, 17500 r·min). -1The supernatant was evaporated to dryness in a vacuum concentrator, then reconstituted with 100 μL of 50% methanol-water mixture, and centrifuged (4 °C, 17500 r·min). -1 (10 min), take the supernatant and inject it.

[0080] 2.2 Serum Samples

[0081] Take 10 μL of serum into an EP tube, add 10 μL of internal standard solution, 200 μL each of methanol and acetonitrile, vortex for 1 min, let stand for 2 h, centrifuge and collect the supernatant (4 ℃, 17500 r·min). -1 (10 min). All supernatant was collected in a vacuum concentrator, evaporated to dryness, reconstituted with 100 μL of 50% methanol-water mixture, and centrifuged (4 °C, 17500 r·min). -1 (10 min), take the supernatant and inject it.

[0082] 2.3 Colon Samples

[0083] Weigh 20.0 mg of colon, add 0.4 mL of ultrapure water, homogenize at low temperature for 5 min, take 200 μL of homogenate, add 10 μL of internal standard solution, vortex for 15 s, add 200 μL each of methanol and acetonitrile, vortex again for 1 min, centrifuge and collect the supernatant (17500 r·min). -1 (10 min, 4 ℃). All supernatant was evaporated to dryness in a vacuum concentrator, then reconstituted with 100 μL of 50% methanol-water mixture, and centrifuged (17500 r·min). -1 (10 min, 4 ℃), take the supernatant for injection.

[0084] 2.4 NCM460 inflammatory cell samples

[0085] Take 200 μL of cell supernatant into an EP tube, add 10 μL of internal standard solution, 200 μL each of methanol and acetonitrile, vortex for 1 min, incubate at 4 ℃ for 2 h, centrifuge and collect the supernatant (17500 r·min). -1 (4 ℃, 10 min). All supernatant was evaporated to dryness in a vacuum concentrator, then reconstituted with 100 μL of 50% methanol-water mixture, and centrifuged (17500 r·min). -1 (4 ℃, 10 min), take the supernatant for injection.

[0086] Example 3 Methodological Determination

[0087] 1. Specificity determination

[0088] 1.1 Method

[0089] Take blank matrix samples from each biological sample, process them according to the sample pretreatment method, and perform LC-MS analysis according to the method. Record the chromatograms of the blank matrix, the blank matrix with reference standards (known concentrations of tryptophan and metabolite reference standards) and internal standard, and the test sample with internal standard solution. Observe the mutual interference between endogenous substances in the blank matrix and each component and internal standard.

[0090] 1.2 Results Analysis

[0091] Under these assay conditions, the retention times of TRP, KYN, KYNA, 5-HT, 5-HIAA, 3-AA, 3-HK, IAA, IPA, and XA in feces were 7.69, 7.25, 7.72, 7.00, 8.25, 7.93, 6.10, 10.04, 10.61, and 7.45 min, respectively; the retention times of the above substances in serum were 7.33, 6.94, 7.39, 6.69, 7.88, 7.60, 5.50, 9.73, 10.30, and 7.10 min, respectively; and the retention times of the above substances in the colon were 7.90, 7.42, 7.94, 7.12, 8.33, 7.89, 6.73, 10.14, 10.71, and 7.65 min, respectively. The retention times of the above substances in NCM460 inflammatory cells were 7.67, 7.35, 7.72, 7.14, 8.26, 7.94, 6.09, 10.07, 10.62, and 7.43 min, respectively. Figures 1-8 The specificity spectral results show that the method has good specificity, and the 10 analytes in each biological sample are not affected by other substances during the retention time.

[0092] 2. Standard Curve

[0093] 2.1 Methods

[0094] Separately, a series of mixed standard curve working solutions for each component were prepared into standard curve samples of a series concentrations according to the pretreatment methods for each biological sample. These samples were then injected for detection, and the chromatograms were recorded. The working equations for the standard curves of the 10 analytes were obtained by linearly fitting the ratio of the peak area of ​​the analyte to the peak area of ​​the internal standard (Y) and the sample concentration (X).

[0095] 2.2 Results Analysis

[0096] The working equations for the 10 analytes in rat feces, serum, colon, and LPS-induced NCM460 inflammatory cell models are shown in Tables 3-6. The results indicate that the standard curves for the 10 analytes in each biological sample showed good linearity within their respective linear ranges, with r values ​​all greater than 0.99.

[0097] Table 3 Standard curves for 10 analytes used in fecal samples

[0098]

[0099] Table 4 Standard curves for 10 analytes used in serum sample determination

[0100]

[0101] Table 5 Standard curves for 10 analytes used in colon samples.

[0102]

[0103] Table 6 Standard curves for 10 analytes used in the determination of NCM460 inflammatory cell samples

[0104]

[0105] 3. Matrix effect, extraction recovery, intra-day / inter-day precision, intra-day / inter-day accuracy

[0106] 3.1 Method

[0107] 3.1.1 Matrix effect

[0108] The peak area obtained by directly injecting a reference solution and internal standard of known concentration is denoted as A. The blank matrix of each biological sample, after being processed according to section 1. Preparation of Blank Biological Matrix in Example 2, is then supplemented with a reference solution and internal standard of known concentration, and the resulting peak area is denoted as B. The ratio of B to A is the matrix effect. Following this method, quality control samples (blank matrix + reference standard + internal standard, 5 samples of each concentration) at low, medium, and high concentrations were measured, and the matrix effects of 10 components at low, medium, and high concentrations were obtained.

[0109] 3.1.2 Absolute recovery rate (extraction recovery rate)

[0110] Five quality control samples of known low, medium, and high concentrations were taken and processed according to the procedure in "2. Sample Pretreatment" of Example 2. The peak area obtained by injection is C; the peak area obtained by direct injection of the reference solution and internal standard of known concentration is A. The ratio of C to A is the absolute recovery rate. The three concentrations of each component in the quality control samples of low, medium, and high concentrations were measured according to this method, and the results were recorded.

[0111] 3.1.3 Intra-day precision / accuracy, inter-day precision / accuracy

[0112] Take three known concentrations of quality control samples (five samples of each concentration) of low, medium and high, and process them according to the procedure in "2. Sample Pretreatment in Example 2". Measure them on the same day, record the peak area, and substitute it into the working equation of the standard curve to obtain the actual concentration of each component. Calculate the RSD of each component in the five samples, which is the intra-day precision of the quality control samples. The ratio of the actual concentration of each component to the known concentration is the intra-day accuracy of the quality control samples.

[0113] Three quality control samples (five samples each at low, medium, and high concentrations) were prepared on different dates, and a total of three batches (45 samples in total) were measured. The samples were processed according to the procedure in "2. Sample Pretreatment in Example 2". The peak areas were recorded and substituted into the standard curve working equation to obtain the actual concentration of each component. The RSD (relative standard deviation) of each component in the three batches of 15 samples was calculated, which is the intra-day precision of the quality control samples. The ratio of the actual concentration of each component to the known concentration is the intra-day accuracy of the quality control samples.

[0114] 3.2 Results Analysis

[0115] The matrix effects of all substances were within the range of 80%-120%, the extraction recoveries were all greater than 50%, the intra-day / inter-day precision RSDs were all less than 15%, and the intra-day / inter-day accuracys were all greater than 80%. All methodological indicators for the 10 substances met the requirements for quantification of biological samples. The matrix effects, extraction recoveries, intra-day / inter-day precisions, and intra-day / inter-day accuracy of fecal, serum, colon, and NCM460 inflammatory cell samples are shown in Tables 7-10.

[0116] Table 7. Matrix effect, extraction recovery, intra-day / inter-day precision, and intra-day / inter-day accuracy of fecal samples.

[0117]

[0118] Table 8. Serum sample matrix effect, extraction recovery, intra-day / inter-day precision, intra-day / inter-day accuracy

[0119]

[0120] Table 9. Matrix effect, extraction recovery, intra-day / inter-day precision, and intra-day / inter-day accuracy of colon samples.

[0121]

[0122] Table 10 Matrix effect, extraction recovery rate, intra-day / inter-day precision, and intra-day / inter-day accuracy of NCM460 inflammatory cell samples

[0123]

[0124] 4. Stability

[0125] 4.1 Methods (Stability under different conditions)

[0126] (1) Stability within the autosampler

[0127] Five samples of each of three concentrations (low, medium, and high) were taken and processed according to the procedure in "2. Sample Pretreatment" in Example 2. The sample solution was placed in an autosampler (4 °C) and measured at 0, 6, 12, and 24 h. The RSD of each component concentration after different placement times was calculated to obtain the stability of the quality control sample after different placement times in the autosampler.

[0128] (2) Sample stability under repeated freeze-thaw cycles

[0129] Five samples of each of three concentrations (low, medium, and high) were frozen at -20 °C, then thawed and processed according to the procedure in "2. Sample Pretreatment" of Example 2 before injection and analysis. The quality control samples were subjected to three freeze-thaw cycles, and the RSD of each component concentration after the three freeze-thaw cycles was calculated to obtain the freeze-thaw stability of the quality control samples.

[0130] (3) Long-term frozen stability of samples

[0131] Three quality control samples (20 samples of each concentration) at low, medium, and high concentrations were collected and stored at -20 °C. Five samples were taken out at 0, 5, 15, and 30 days respectively, and processed according to the procedure in "2. Sample Pretreatment" of Example 2, and then injected for analysis. The RSD of each component concentration after long-term freezing was calculated to obtain the stability of the quality control samples after long-term cryopreservation.

[0132] 4.2 Results Analysis

[0133] The stability of 10 substances in fecal, serum, colon, and NCM460 inflammatory cell samples at low, medium, and high concentrations in quality control samples after being placed in an autosampler (4 ℃) for different times (0, 6, 12, 24 h), the stability after three freeze-thaw cycles (-20 ℃ freezing-room temperature thawing, repeated three times), and the stability after long-term frozen storage of samples for different times (0, 5, 15, 30 days) were all less than 15%, as shown in Tables 11-14. This indicates that the stability of the 10 substances in different biological samples all met the determination requirements.

[0134] Table 11 Stability of fecal samples under different conditions

[0135]

[0136] Table 12 Stability of serum samples under different conditions

[0137]

[0138] Table 13 Stability of colon samples under different conditions

[0139]

[0140] Table 14 Stability of NCM460 samples under different conditions

[0141]

[0142] Application Example 1: Methodological Application—Determination of Tryptophan and Related Metabolites Content in Various Biological Samples

[0143] 1. Method

[0144] 1.1 Determination of tryptophan and related metabolites in rat feces, serum, and colon tissue samples

[0145] A ulcerative colitis (UC) model was established using a combination of symptoms and treatment. Rats with spleen deficiency and dampness-induced ulcerative colitis (UC) were induced using sodium dextran sulfate (DSS) in combination with diet and environment. Low, medium, and high doses of Shenling Baizhu powder (SLBZS) (0.945, 1.89, and 3.78 g·kg⁻¹) were administered. -1 ·d -1 ) and the positive control drug sulfasalazine (0.2 g·kg -1 ·d -1 The intervention lasted for 30 days. After the administration was completed, fecal, serum, and colon tissue samples were collected from rats in the normal group, UC model group, positive control drug sulfasalazine group, and low, medium, and high dose groups of Shenling Baizhu Powder to determine the tryptophan and its metabolites in the samples.

[0146] 1.2 Determination of tryptophan and related metabolite content in NCM460 inflammatory cell samples

[0147] 40 μg·mL -1 An inflammation model was established by stimulating NCM460 cells with LPS, and the cells were treated with serum containing 5%, 10%, and 20% Shenling Baizhu Powder and 50 μg / mL of the drug. -1 The cell supernatant was treated with tryptophan, and the content of tryptophan and its metabolites in the cell supernatant was determined using the UPLC-MS / MS chromatographic and mass spectrometric conditions described in "Example 1".

[0148] 2. Results Analysis

[0149] 2.1 Content of tryptophan and its related metabolites in feces of each group

[0150] The results showed that compared with the normal group, the KYNA content in the model group was significantly increased (P<0.05), while the contents of 3-AA, IAA, and IPA were significantly decreased (P<0.05). Compared with the model group, after drug intervention, low-dose SLBZS increased the content of 3-AA (P<0.05), medium-dose SLBZS decreased the KYNA content, and high-dose SLBZS significantly increased the contents of TRP, 3-AA, and IPA (P<0.05) and decreased the contents of 5-HT and 5-HIAA (P<0.05). Compared with the model group, there were no statistically significant differences in the contents of other substances after drug intervention, but all showed significant increases or decreases. Figure 9 ).

[0151] 2.2 Serum tryptophan and its related metabolites in each group

[0152] The results showed that compared with the normal group, the levels of TRP, XA, and IAA in the model group were significantly decreased (P<0.05), while the levels of KYN, 5-HT, and 5-HIAA were significantly increased (P<0.05). Compared with the model group, the levels of TRP, XA, and IAA were significantly increased after SLBZS intervention (P<0.01, P<0.05). High-dose SLBZS significantly reduced KYNA levels (P<0.05), while low and medium-dose SLBZS significantly reduced KYN and 5-HIAA levels (P<0.05). Medium and high-dose SLBZS significantly reduced 5-HT levels (P<0.05), and medium and high-dose SLBZS significantly increased 3-AA and IPA levels (P<0.05). 3-HK could not be quantified because its serum level was below the limit of quantification. Figure 10 The results suggest that SLBZS can affect the tryptophan metabolism pathway in UC model rats, thereby treating UC.

[0153] 2.3 Content of tryptophan and its related metabolites in the colon of each group

[0154] The results showed that compared with the normal group, the model group had significantly lower levels of TRP and IPA (P<0.05), and significantly higher levels of KYN, KYNA, and 5-HIAA (P<0.05). After low- and high-dose SLBZS intervention, KYNA levels were significantly lower (P<0.05). After low- and medium-dose SLBZS intervention, KYN, 5-HT, and 5-HIAA levels were significantly lower (P<0.05). After medium-dose SLBZS intervention, IAA and IPA levels were significantly higher (P<0.05). The levels of 3-AA and 3-HK in colonic tissue were below the limit of quantification and could not be quantified. The levels of other substances in colonic tissue showed no statistically significant differences due to large error values. Figure 11 ).

[0155] 2.4 Content of tryptophan and its related metabolites in NCM460 inflammatory cells of each group

[0156] The results showed that, compared with the normal group, the contents of TRP and IPA were significantly decreased (P<0.05), while the contents of KYN, KYNA, 5-HT, and 5-HIAA were significantly increased (P<0.05). Compared with the model group, the contents of SLBZS and 50 μg·mL⁻¹ were significantly increased. -1 TRP levels were significantly increased after TRP intervention (P<0.01, P<0.05), with low-dose SLBZS (50 μg·mL⁻¹) showing the highest levels. -1 The TRP group significantly increased the levels of IAA and XA (P<0.05, P<0.01), while low, medium, and high doses of SLBZS significantly decreased the levels of KYN, KYNA, 5-HT, and 5-HIAA (P<0.05). Figure 12 3-HK could not be quantified because its concentration in the cell supernatant was below the limit of quantification. Although the concentrations of 3-AA and IPA varied to some extent, there were no statistically significant differences.

[0157] The above-described embodiments are merely preferred embodiments of the present invention, and while the descriptions are specific and detailed, they should not be construed as limiting the scope of the invention. It should be noted that those skilled in the art can make various modifications and improvements without departing from the concept of the present invention, and these all fall within the scope of protection of the present invention. Therefore, the scope of protection of the present invention should be determined by the appended claims.

Claims

1. A method for the simultaneous determination of 10 tryptophan metabolites using liquid chromatography-mass spectrometry, characterized in that: The 10 tryptophan metabolites are TRP, KYN, KYNA, 5-HT, 5-HIAA, 3-AA, 3-HK, IAA, IPA, and XA; the method includes the following steps: S1. Prepare blank biological matrix and perform sample pretreatment for samples 1-4 respectively; S2. The samples processed in S1 were subjected to methodological determination using mass spectrometry and liquid chromatography-mass spectrometry.

2. The method according to claim 1, characterized in that: In step S1, sample 1 is a fecal sample, sample 2 is a serum sample, sample 3 is a colon sample, and sample 4 is an NCM460 inflammatory cell sample.

3. The method according to claim 2, characterized in that: The method for preparing the blank biological substrate in step S1 is as follows: Sample 1 and Sample 3: Weigh 20.0 mg of sample, add 0.4 mL of ultrapure water, homogenize for 5 min, centrifuge, and collect the supernatant. Add 20 mg of activated carbon and 20 mg of calcite to the supernatant, and stir on a magnetic stirrer for 2 h. Centrifuge again and collect the supernatant, which is the blank matrix. The centrifugation parameters are: 17500 r·min. -1 4 ℃, 10 min; Samples 2 and 4: 10 mg each of activated carbon and calcite were added to every 100 μL of sample. The mixture was stirred on a magnetic stirrer for 2 hours, centrifuged, and the supernatant was collected. This process was repeated 4 times. The supernatant collected after the last centrifugation was used as the blank matrix. The centrifugation parameters were: 17500 r·min -1 4 ℃, 10 min.

4. The method according to claim 2, characterized in that: The sample pretreatment method described in step S1 is as follows: Samples 1 and 3: Weigh 20.0 mg of sample, add 0.4 mL of ultrapure water, homogenize for 5 min, then take 200 μL of homogenate, add 10 μL of internal standard solution, vortex for 15 s, then add 200 μL each of methanol and acetonitrile, vortex again for 1 min, centrifuge, collect the supernatant, evaporate the supernatant to dryness, add 100 μL of 50% methanol-water solution to redissolve, centrifuge again, and collect the supernatant, which is the test solution; the centrifugation parameters are: 17500 r·min -1 4 ℃, 10 min; the homogenization temperature is 3-6 ℃; Sample 2: Take 10 μL of sample into an EP tube, add 10 μL of internal standard solution, 200 μL each of methanol and acetonitrile, vortex for 1 min, let stand for 2 h, centrifuge, collect the supernatant, evaporate the supernatant to dryness, add 100 μL of 50% methanol-water to reconstitute, centrifuge again, and collect the supernatant, which is the test solution; the centrifugation parameters are: 17500 r·min -1 4 ℃, 10 min; Sample 4: Take 200 μL of sample supernatant into an EP tube, add 10 μL of internal standard solution, 200 μL each of methanol and acetonitrile, vortex for 1 min, and let stand in a refrigerator at 4 ℃ for 2 h. After centrifugation, take the supernatant, evaporate the supernatant to dryness, add 100 μL of 50% methanol-water to reconstitute, centrifuge again, and take the supernatant, which is the test solution; the centrifugation parameters are: 17500 r·min -1 4 ℃, 10 min.

5. The method according to claim 1, characterized in that: The mass liquid chromatography-mass spectrometry (MS / MS) used in step S2 includes chromatography and mass spectrometry. The chromatographic parameters are as follows: mobile phase: 0.05% formic acid-acetonitrile; flow rate: 0.1 mL / min. -1 Column temperature: 40 ℃; Injection volume: 1 μL; ACE C18 column: 100 mm × 2.1 mm, 3 μm; Gradient elution of all substances in positive ion mode; The parameters of the mass spectrometer are as follows: curtain gas: 35 psi, 160.88 kPa; nebulizer gas: 45 psi, 301.28 kPa; auxiliary heater: 45 psi, 301.28 kPa; ionization temperature: 500 ℃; spray voltage: 5500 V.

6. The method according to claim 1, characterized in that: The methodological determination described in step S2 includes the following steps: A. Specificity determination: Detection of chromatograms of blank matrix, blank matrix with reference standard and internal standard, and test sample with internal standard solution to assess the interference between endogenous substances and target components and internal standards; B. Establishment of standard curves: Prepare a series of standard curve samples with different concentrations. Use the ratio of the peak area of ​​the analyte to the peak area of ​​the internal standard as the Y-axis and the concentration as the X-axis to perform linear regression and establish the standard curve equations for 10 components. C. Matrix effect assessment: The peak area measured by direct injection of the control solution is A, and the peak area measured by injection of the blank matrix with internal standard is B. The B / A ratio is calculated to assess the matrix effect at different concentrations. D. Determination of absolute recovery: The peak area measured by injecting the quality control sample after extraction is C, and the peak area measured by directly injecting the control solution is A. The C / A ratio is calculated to evaluate the extraction recovery rate. E. Precision / Accuracy Measurement: Intraday precision / accuracy: Five quality control samples with different concentrations were measured on the same day, and the RSD and the ratio of actual concentration to theoretical concentration were calculated. Intraday precision / accuracy: Three batches of quality control samples with different concentrations were measured on different days, and the RSD and the ratio of actual concentration to theoretical concentration were calculated. F. Stability assessment: In-system stability of the autosampler: RSD changes were investigated at 4 °C for 0–24 h. Repeated freeze-thaw stability: The RSD was measured after three freeze-thaw cycles at -20 °C. Long-term freezing stability: RSD was measured at different time points after storage at -20 ℃ for 0-30 days.

7. The application of the method according to claim 1 in detecting the content of tryptophan and its metabolites.

8. The application according to claim 7, characterized in that: When the test sample is feces, serum, or colon tissue, the steps are as follows: (1) Model construction: A UC model was established using sodium dextran sulfate combined with dietary and environmental interventions; (2) Drug intervention: The model rats were randomly divided into the UC model group, the positive control group and the Shenling Baizhu powder group, and were administered the drug for 30 consecutive days; (3) Sample collection; (4) Detection.

9. The application according to claim 8, characterized in that: The positive control group mentioned in step (2) is the positive control drug sulfasalazine, and the dosage of sulfasalazine is 0.2 g·kg. -1 ·d -1 The dosage of the aforementioned Shenling Baizhu Powder is 0.945-3.78 g·kg. -1 ·d -1 .

10. The application according to claim 7, characterized in that: When the sample being tested is NCM460 inflammatory cells, the procedure is as follows: use 40 μg / mL -1 An inflammation model was established by stimulating NCM460 cells with LPS, and the cells were treated with serum containing 5%-20% Shenling Baizhu powder and 50 μg / mL of the drug. -1 Intervention with tryptophan.